An international research team has created a diagnostic blood test that detects Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI). The accuracy rates are exceedingly high, greater than 96% for AD and 87% for MCI. Unlike previously devised tests which measured a single biomarker, the HKUST test measures 21 different proteins which capture multiple biologic pathways involved in the development of AD. Specifically, the test detects brain amyloid pathology.
Beyond making a diagnosis, these researchers believe the blood test will also help monitor disease progression. This will be a huge win for individual patients in their battles with this disease and will be an asset in bringing new and more effective treatments to the market.
Further, it may allow more personalized approaches for patients as it conveys information on the molecular changes of AD that vary in different individuals and between ethnicities.
Currently the diagnosis of Alzheimer’s Disease and Mild Cognitive Impairment is made by lengthy and expensive neuropsychological examinations, PET scans with Amyvid and spinal taps. While these methods aid in the diagnosis of AD and MCI, they do not offer information about disease progression and response to treatment. A simple blood test will revolutionize the detection and treatment of AD and MCI.
If you suspect you have AD or MCI or if you already have the diagnosis, the BeCare Neuro App can help screen you to determine if you need further evaluation and monitor your disease progression if you have the diagnosis.